Kosuke Sawami
Nabeshima, 8498501, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Risk management of cardiovascular disease in older patients with diabetes.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: August 23, 2025
Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy.
Journal: Circulation. Heart failure
Published: August 28, 2024
Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives.
Journal: Cardiovascular diabetology
Published: July 16, 2024
Association Between Clonal Hematopoiesis and Left Ventricular Reverse Remodeling in Nonischemic Dilated Cardiomyopathy.
Journal: JACC. Basic to translational science
Published: August 30, 2023
Are There Any "Tips" for Better Joint Risk Factor Control in Patients With Diabetes?
Journal: JACC. Heart failure
Published: July 13, 2023
An evidence review project for food with function claims ~Challenges of the Japan society for vascular failure for the promotion of adequate evidences for food with function claims.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: June 22, 2023
Myocardial DNA Damage Predicts Heart Failure Outcome in Various Underlying Diseases.
Journal: JACC. Heart failure
Published: June 22, 2023
Glimepiride: an old antidiabetic medication with potential as a new cardiovascular therapeutic?
Journal: European journal of preventive cardiology
Published: March 21, 2023
Letter by Sawami et al Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
Journal: Circulation
Published: February 06, 2023
Recent understandings about hypertension management in type 2 diabetes: What are the roles of SGLT2 inhibitor, GLP-1 receptor agonist, and finerenone?
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: December 29, 2022
How to Measure DELIVERed Benefits of Dapagliflozin in the Management of HFmrEF/HFpEF?
Journal: JACC. Heart failure
Published: November 22, 2022
Appropriate mineralocorticoid receptor antagonism and salt restriction are essential for primary aldosteronism therapy.
Journal: Hypertension research : official journal of the Japanese Society of Hypertension
Published: October 19, 2022
Last Updated: 09/26/2026